/PRNewswire/ LAIX Inc. ("LAIX" or the "Company") (NYSE: LAIX), an artificial intelligence (AI) company in China that creates and delivers products and.
Many observers view Pakistan as a test case for China’s assertive overseas expansion plans. But sometimes, it is Chinese players who have had to adapt to Islamabad’s realities.
Share this article
Share this article
TORONTO, May 3, 2021 /PRNewswire/ -
Mountain Valley MD Holdings Inc. (the
Company or
MVMD ) (CSE: MVMD) (FRA: 20MP) (OTCQB: MVMDF) is pleased to announce that the Company has filed a novel cancer adjuvant patent and is proceeding with pre-clinical trials with third-party cancer Contract Research Organizations (CROs) in triple-negative breast cancer, metastatic melanoma, and lung carcinoma.
Summary
MVMD files cancer patent for direct intratumoral injection, intravenously, infusions or instillations as adjuvants for broad chemotherapeutic to immunotherapeutic cancer regimens.
The Company is proceeding with three separate pre-clinical trials with specialized third-party cancer CROs: (1) triple-negative breast cancer; (2) metastatic melanoma; and (3) Lewis Lung Carcinoma as a proxy for non-small cell lung carcinoma.
纪念|睹物忆汪公——怀念汪庆正先生_上海博物馆 sohu.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from sohu.com Daily Mail and Mail on Sunday newspapers.
Share this article
Share this article
SHANGHAI, April 27, 2021 /PRNewswire/ LAIX Inc. ( LAIX or the Company ) (NYSE: LAIX), an artificial intelligence (AI) company in China that creates and delivers products and services to popularize English learning, today announced its unaudited financial results for the fourth quarter and full year ended December 31, 2020.
Fourth Quarter 2020
Gross billings
[1] for the fourth quarter of 2020 were RMB171.1 million (US$26.2 million), a 33.4% decrease from RMB257.1 million for the previous quarter and a 50.0% decrease from RMB341.9 million for the same quarter last year.
Net revenues for the fourth quarter of 2020 were RMB235.5 million (US$36.1 million), a 1.7% decrease from RMB239.4 million for the previous quarter and a 1.8% increase from RMB231.4 million for the same quarter last year.